Application of MOG(1-125) Protein in the Research of MOG Antibody-Associated Diseases

I. Introduction

Myelin oligodendrocyte glycoprotein (MOG) is a myelin protein specifically expressed on the surface of oligodendrocytes in the central nervous system, localized to the outermost layer of myelin. Composed of 218 amino acids, it belongs to the immunoglobulin superfamily. Despite its low abundance, accounting for less than 0.05% of myelin components, MOG plays a critical role as an important autoantigen in inflammatory demyelinating diseases. Recent studies have revealed that MOG antibody-positive patients exhibit unique clinical phenotypes and pathological features, gradually being defined as a distinct disease entity—MOG antibody-associated disease (MOG-AD). The MOG(1-125) protein, a recombinant protein containing the core epitopes of the extracellular domain, holds significant value in antibody detection and mechanistic research. This article systematically reviews the antibody detection, pathogenesis, clinical manifestations, treatment, and prognosis of MOG-AD, with a focus on the application of MOG(1-125) protein in related studies.

II. Structure and Function of MOG Protein

The MOG protein consists of 218 amino acids, with a structure comprising an extracellular immunoglobulin-like domain, a transmembrane region, and an intracellular segment. The extracellular domain (amino acids 1-125) contains a complete immunoglobulin-like domain (IgV-like domain), which is the primary target for autoantibody recognition. The biological functions of MOG are not fully understood, but its structural features suggest potential roles in maintaining myelin stability, regulating the cytoskeleton, and activating complement. Despite its low expression, animal studies have confirmed that MOG can act as an autoantigen to induce experimental autoimmune encephalomyelitis (EAE), with generated MOG antibodies exhibiting clear pathogenicity.

III. Evolution of MOG Antibody Detection Methods

The detection methods for MOG antibodies have undergone significant advancements. Early studies used the extracellular domain of MOG synthesized in E. coli as an antigen, employing enzyme-linked immunosorbent assay (ELISA) or Western blot to detect antibodies. These methods could only identify linear epitopes of MOG, missing the more pathogenic conformational epitopes. Animal experiments confirmed that only MOG antibodies recognizing conformational epitopes are pathogenic.

Cell-based assays (CBA) involve transfecting engineered cells (e.g., HEK293 cells) with RNA encoding full-length MOG or the MOG(1-125) fragment, enabling the expression of MOG protein with correct spatial conformation on the cell membrane. Immunofluorescence is then used to detect antibodies targeting conformational epitopes in patient serum. CBA significantly improves the specificity and sensitivity of detection, becoming the internationally recommended standard method. The 2018 international expert consensus explicitly recommends CBA for MOG antibody detection and establishes diagnostic criteria for MOG-AD based on this method. The MOG(1-125) protein, as a core fragment containing the complete extracellular domain, is widely used in CBA detection reagents.

IV. Application of MOG(1-125) Protein in Antibody Detection

The MOG(1-125) protein covers the entire amino acid sequence of the MOG extracellular domain, including the complete immunoglobulin-like domain, which can fold correctly to form the native spatial conformation. This fragment retains the major antigenic epitopes of MOG and can be specifically recognized by pathogenic MOG antibodies. In the CBA detection system, transfection of engineered cells with the MOG(1-125) gene allows the extracellular domain with correct conformation to anchor to the cell membrane, mimicking its natural presentation on oligodendrocytes. MOG antibodies in patient serum bind to the MOG(1-125) protein on the cell surface, enabling visualization through fluorescent-labeled secondary antibodies. Compared to full-length MOG protein, the MOG(1-125) fragment removes the transmembrane and intracellular regions, reducing nonspecific binding and improving detection specificity.

V. Pathogenesis and the Role of MOG(1-125) Protein

The pathogenesis of MOG-AD involves the breakdown of peripheral immune tolerance and autoimmune attacks on the central nervous system. Since MOG is expressed only in the immune-privileged CNS, sensitization may occur when the blood-brain barrier becomes permeable, allowing MOG antigens to leak into the periphery and be recognized by the immune system. Animal studies have found that gut microbiota can assist in the activation of MOG-specific T and B cells, promoting MOG antibody production. When the blood-brain barrier is compromised again, peripherally generated MOG antibodies enter the CNS and bind to MOG on oligodendrocytes, causing myelin damage through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The MOG(1-125) protein, as a soluble antigen, can be used in vitro to study the binding characteristics of MOG antibodies to target antigens, screen pathogenic antibody subtypes, and evaluate the interference effects of candidate drugs on antibody-antigen interactions.

VI. Clinical Phenotypes and Characteristics

MOG-AD exhibits unique epidemiological and clinical features. The antibody positivity rate is approximately 40% in children and 22% in adults, with a slight female predominance and no racial clustering. Clinical phenotypes are strongly age-dependent: children often present with acute disseminated encephalomyelitis (ADEM)-like symptoms, while adults predominantly exhibit optic neuritis (ON). Other phenotypes include myelitis, brainstem encephalitis, and meningitis.

Optic neuritis is the most common phenotype of MOG-AD, with about half of patients presenting bilateral optic nerve involvement at onset. Vision loss is rapid but prognosis is favorable, with a much lower blindness rate compared to AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). Imaging features include anterior optic nerve involvement, often accompanied by optic nerve sheath enhancement and intraorbital soft tissue inflammation, which are highly specific. Myelitis accounts for about 20% of cases, primarily affecting the cervical and thoracic spinal cord, sometimes involving the conus medullaris. MRI shows lesions mostly confined to gray matter, with an "H"-shaped high signal. Encephalitis manifests diversely, including psychiatric symptoms and seizures, with imaging revealing multifocal lesions in the cortex, deep nuclei, and white matter.

VII. Which Manufacturers Provide MOG(1-125) Protein?

Nanjing UA-Biotech Co., Ltd. (UA-Bio) has independently developed "MOG(1-125) Protein, Human", a high-quality recombinant protein reagent specifically designed for studying the structure and function of myelin oligodendrocyte glycoprotein (MOG). This protein covers the extracellular domain (amino acids 1-125) of human MOG, maintaining the complete native conformation and antigenic epitopes. It provides a stable and reliable standardized tool for research on the mechanisms of autoimmune diseases like multiple sclerosis, antibody drug development, and immunoassays.

Nanjing UA-Biotech Co., Ltd. is dedicated to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or application inquiries regarding "MOG(1-125) Protein, Human" (Catalog No.: UA010471), please feel free to contact us.